Models and methods for rapid screening the efficacy of immunoregulating drugs
The PVDF capsule tube model with tumor and immune cells in an animal model addresses the inefficiencies of current immunotherapy screening by enabling rapid and accurate identification of drug biomarkers, facilitating personalized treatment.
Patent Information
- Application Number
- KR1020230106823
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-09-01
- Filing Date
- 2023-08-16
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2043-08-16
AI Technical Summary
Current methods for screening the efficacy of immunomodulatory drugs are time-consuming and fail to accurately target or modulate the immune system, lacking effective screening for immune cell-targeting drugs, which delays drug development and personalized treatment.
A model using a PVDF capsule tube containing tumor and immune cells derived from clinical samples, integrated into an animal model, allows for rapid screening of immunotherapies by detecting immune cell activity and molecular changes through flow cytometry and omics analysis.
Enables rapid and accurate screening of immunotherapies by identifying appropriate biomarkers for drug responsiveness, reducing screening time and providing pharmacokinetic data for clinical precision medicine.
Smart Images

Figure 112023089817529-PAT00001_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to the field of biopharmaceuticals, and in particular to a model, a method, and an application of said model for rapidly screening the efficacy of immunomodulatory drugs. Background Technology
[0002] Currently, drugs with immune-targeting and modulating functions are being developed in large quantities and applied to the treatment of many clinical diseases. Among them, CTLA4 antibody (ipilumumab) and PD1 antibody (Keytruda, Opdivo) are being pioneered in the treatment of tumors such as melanoma, non-small cell lung cancer, small cell lung cancer, and head and neck squamous cell carcinoma; TNFα antibody adalimumab is being applied in the treatment of rheumatoid arthritis and active colitis; and the latest IL12 / IL23p40 antibody Ustekinumab is being applied in the treatment of autoimmune diseases such as psoriasis, inflammatory colitis, and systemic lupus erythematosus. However, not all patients respond well to drugs with such immunomodulatory effects. Furthermore, due to the nature of clinical practice, the requirements regarding timelines and guidelines for treatment plans are extremely high. For instance, typical humanized mouse PDX experiments or the modeling and administration of immune diseases take 2 to 5 months; moreover, these processes fail to meet the demands for patient diversification (selection of various immunotherapies) and can delay the new drug research and development process. Therefore, there is an urgent need for rapid and effective functional screening methods to accurately treat patients and identify drug biomarkers across diverse populations.
[0003] However, all current technical solutions are intended for screening the drug sensitivity of tumor cells to chemotherapy drugs in vivo, and since all experimental subjects are tumor cells and the test drugs are mainly chemotherapy drugs or tumor-targeted drugs (US005676924A, 1997; US005698413A, 1997; CN108351348A, 2017), they cannot satisfy the rapid screening of the immune system to target or modulate the efficacy of the drugs. The problem to be solved
[0004] The problem that the present invention aims to solve is to provide a model and method for screening the efficacy of immunomodulatory drugs in order to overcome the issues where screening the immune system to target or regulate drug efficacy is time-consuming and fails to meet the requirements for accurate treatment of patients. Compared to conventional screening of immunodrug efficacy, the present invention can significantly reduce the screening time and enables accurate treatment of clinical patients by screening appropriate biomarkers for immunodrug responsiveness.
[0005] Conventional experimental subjects applied to drug sensitivity screening for chemotherapy drugs or tumor-targeting drugs are tumor cells, which do not include immune cells or eliminate most immune cells, resulting in a lack of screening methods for drugs that target immune cells or modulate the immune system. This invention develops an animal model through extensive experimentation and detects the effects and mechanisms of immunotherapies, such as anti-tumor, anti-inflammatory, and anti-infectious properties, by regulating the simulated immune system within the animal model. Furthermore, by screening appropriate biomarkers for immunotherapy response, it enables rapid screening of the immune system to target or modulate the efficacy of drugs. means of solving the problem
[0006] The present invention solves the above technical problem through the following technical solution means.
[0007] A first aspect of the present invention provides a PVDF capsule tube containing cells, wherein the cells include tumor cells and immune cells suspended as single cells;
[0008] The above tumor cells and immune cells are derived from fresh tumor tissue or body fluid of a clinical patient;
[0009] In some embodiments of the present invention, the tumor tissue comprises tumor tissue resected by clinical surgery or tumor tissue biopsied;
[0010] In some embodiments of the present invention, the body fluid comprises one or more of blood, bone marrow, thoracic and ascites fluid, and cerebrospinal fluid.
[0011] In some embodiments of the present invention, the average protein permeability of the capsule tube is 300 to 1000 Kda, preferably 500 to 700 Kda.
[0012] In some embodiments of the present invention, the capsule tube must undergo activation, ultrapure water rinsing, and high-pressure sterilization before use, and the activation method is preferably anhydrous ethanol.
[0013] In some embodiments of the present invention, the immune cells are autoimmune cells concentrated by classifying a single-cell suspension, and the tumor cells are tumor cells that flow through during the classification of the single-cell suspension;
[0014] The above single-cell suspension is derived from tumor-infiltrating lymphocytes within the patient's solid tumor tissue, and / or peripheral blood mononuclear cells within the patient's peripheral blood.
[0015] In some specific embodiments of the present invention, the classification device used for classification is,
[0016] (1) Classification magnetic beads, preferably Anti-CD45 MicroBeads human, and / or Anti-Fibroblast MicroBeads human; and
[0017] (2) Classification device, preferably an LS column; is included.
[0018] In some specific embodiments of the present invention, the cell suspension is,
[0019] (1) A step of removing non-tumor tissue and necrotic tissue from the tumor sample, cutting the tumor sample into tissue pieces 1 to 2 mm in size, rinsing with HBSS buffer containing 1% PSB and centrifuging, and collecting the tumor tissue pieces;
[0020] (2) digesting with collagenase, terminating digestion with a serum-containing medium, collecting the cell suspension; centrifuging to remove the supernatant, and collecting the cell pellet;
[0021] (3) lysate with 3 to 5 times the volume of erythrocyte lysis solution, centrifuge to remove the supernatant, collect the cell pellet, and repeat erythrocyte lysis twice; wherein the erythrocyte lysis solution comprises 139.6 mmol / L NH4Cl and 16.96 mmol / L Tris pH 7.2; and
[0022] (4) The cell pellet is resuspended in PBS containing 1% FBS, centrifuged to remove the supernatant, the cell pellet is collected, and the cell concentration is adjusted; this step is prepared.
[0023] In some embodiments of the present invention, the ratio of tumor cells to immune cells is in the range of 1.5:1 to 15:1, preferably 1.5:1 to 9:1.
[0024] In some embodiments of the present invention, the proportion of CD8+T cells among the immune cells is 0.5% or more, preferably 0.5% to 15%; and / or, the viability of the immune cells is >20%.
[0025] A second aspect of the present invention provides an animal model, said animal model preferably contains said capsule tube subcutaneously or at the same time.
[0026] In some embodiments of the present invention, the animal is a mouse.
[0027] In some specific embodiments of the present invention, the mouse is an immunodeficient mouse such as a Balb / c Nude mouse, NCG mouse, NSG mouse, or Nod-scid mouse.
[0028] In some embodiments of the present invention, the number of capsule tubes is 1 to 8.
[0029] A third aspect of the present invention provides a method for rapidly screening the efficacy of an immunomodulatory drug, said method,
[0030] (1) Administer the test drug to the above mouse model;
[0031] The above test drug is an immunomodulatory drug comprising one or more of solid, semi-solid, and liquid;
[0032] The method of administering the above test drug includes a step comprising one or more of intravenous injection, oral gastrointestinal feeding, intraperitoneal injection, and subcutaneous injection;
[0033] (2) Detect total cell activity or immune cell activity, relative ratio of tumor cells to immune cells and cell phenotype, and cell phenotype of tumor cells and immune cells within the capsule tube;
[0034] The above total cell activity or immune cell activity is preferably detected by CTG (CellTiter Glo) chemiluminescence;
[0035] The above relative ratio and cell phenotype are preferably detected by flow cytometry (FACS); and
[0036] (3) Detect molecular biological information of tumor cells and immune cells within the capsule tube;
[0037] The above biological information preferably includes a step of being detected by DNA-seq and / or RNA-seq.
[0038] In some specific embodiments of the present invention, steps (2) and (3) are not in a sequential order;
[0039] Preferably, in step (2), the FACS,
[0040] A step of performing antibody labeling, wherein the antibody comprises one or more of 7AAD, CD45, CD3, CD8, CD270, CD33, CD38, CD20, PDL1, PD1, CD68, and CD25;
[0041] Detecting by flow cytometry, wherein the FACS is performed by adding PBS containing 2% FBS after the antibody labeling is completed and then detecting in a machine; and
[0042] The software analyzes data, and preferably includes one or more steps of the software being Flowjo.
[0043] A fourth aspect of the present invention provides an application of a capsule tube according to a first aspect in the manufacture of an animal model for rapidly screening the efficacy of an immunomodulatory drug.
[0044] In some embodiments of the present invention, the animal model is preferably an immunodeficient mouse.
[0045] In some specific embodiments of the present invention, the animal model can perform drug screening on 1 to 8 patients, preferably 1 to 4 patients, at the same time.
[0046] Each preferred embodiment of the present invention can be obtained by arbitrarily combining each of the above preferred conditions on a basis consistent with common sense in the art.
[0047] All reagents and raw materials used in the present invention are available on the market. Effects of the invention
[0048] The positive progressive effects of the present invention are as follows.
[0049] The present invention establishes an animal model containing a capsule tube to perform screening of drugs for targeting and regulating the immune system. The model and method provided by the present invention provide a rapid screening method for the sensitivity and efficacy of immunotherapies in clinical patients, and acquire pharmacokinetic data from the animal in vivo model, paired flow cytometry data for multicellular subpopulation phenotype identification, and multi-omics analysis data to provide a rapid and effective method for studying functions and mechanisms for clinical precision medicine and new drug research and development. Brief explanation of the drawing
[0050] Figure 1 is a schematic diagram of the “IO (Immuno-Oncology Fast In Vivo Efficacy test) technology for rapid screening of immunotherapies,” taking tumor immunity as an example: patient tumor tissue was taken and processed to seal mini-capsules so that tumor cells and autoimmune cells were mixed in a certain ratio (1.5:1 to 15:1 recommended), and drug treatment was performed by subcutaneously or orthotopically inoculating immunodeficient mice. After 5 to 14 days, the mini-capsules were taken and total cell activity detection, flow cytometry (FACS) cell subpopulation ratios and phenotype identification, and various omics (e.g., transcriptome) analyses were performed before and after drug administration. In the case of autoimmune disease, immune cells were taken from the patient's inflammatory tissue (e.g., lymph nodes) and peripheral blood, FACS was performed to detect cell phenotype identification, and the capsules were sealed. After inoculation and administration in vivo, mini-capsules were taken 5 to 14 days later to detect immune cell activity, perform flow cytometry (FACS) to determine cell subpopulation ratios and phenotype identification, and perform various omics (e.g., transcriptome) analyses before and after drug use. Figure 2 (Example 1) is the phenotype detection of a single-cell suspension of tumor tissue (mini-capsule tube) by flow cytometry on day 0 in one ovarian cancer patient. Figure 3 (Example 1) shows the detection of the survival rate of all cells (including tumor cells and immune cells) inside a capsule tube by CTG (CellTiter-Glo) chemiluminescence on day 10 in an ovarian cancer patient. Figure 4 (Example 1) shows the phenotypic detection and analysis of a single-cell suspension of tumor tissue in a capsule tube by flow cytometry (FACS) on day 10 in an ovarian cancer patient. Figure 5 (Example 2) shows the phenotype detection of a single-cell suspension of tumor tissue (mini-capsule tube) by flow cytometry on day 0 in one ovarian cancer patient. Figure 6 (Example 2) shows the detection of the survival rate of all cells (including tumor cells and immune cells) in a capsule tube by the CTG method on day 10 in an ovarian cancer patient. Figure 7 (Example 2) shows the phenotype of tumor tissue (tumor cells and immune cells) inside a mini capsule tube detected by FACS on day 10 in an ovarian cancer patient. Figure 8 (Example 3) shows the detection of different types of phenotypes (before purification, after tumor cell purification, after immune cell purification, and after immune cell addition to the tumor sample) of a single-cell suspension of tumor tissue by flow cytometry on day 0 in one ovarian cancer patient. Figure 9 (Example 3) shows the detection of the viability of all cells (including tumor cells and immune cells) in a capsule tube by the CTG method on day 10 in an ovarian cancer patient (before purifying the tumor tissue, after adding immune cells to the tumor sample). Figure 10 (Example 3) shows the phenotype detection of tumor tissue (tumor cells and immune cells) in each mini capsule tube by FACS on day 10 in an ovarian cancer patient. Figure 11 (Example 4) shows the phenotype detection of a single-cell suspension of tumor tissue (mini-capsule tube) by flow cytometry on day 0 in a lung cancer patient. Figure 12 (Example 4) shows the detection of the survival rate of all cells (including tumor cells and immune cells) in a capsule tube by the CTG method on day 14 in a lung cancer patient. Figure 13 (Example 4) shows the phenotype detection of tumor tissue (tumor cells and immune cells) inside a mini capsule tube by FACS on day 14 in a lung cancer patient. Fig. 14 (Example 5) shows the phenotype detection of a single-cell suspension (mini-capsule tube) of tumor tissue (peripheral blood) by flow cytometry on day 0 in two AML patients. Fig. 15 (Example 5) shows the detection of total cell (including tumor cells and immune cells) viability in a capsule tube by the CTG method on day 14 in two AML patients. a of Fig. 16 (Example 5) is the phenotype of tumor tissue (tumor cells and immune cells) in a mini capsule tube detected by FACS on day 14 in one immune-responsive 124# patient, and b is the CD8+T live cell ratio in two AML 124# patients (immune-responsive) and 123# patients (immune-non-responsive) analyzed by FACS on day 14. The heatmap in a of Fig. 17 (Example 5) shows the transcriptome differential gene signaling pathways on day 0 in two AML patients; b is a comparative analysis of tumor proliferation level, angiogenesis level, neutrophil activation level, and effector (T) cell level biomarkers in the differential gene expression cluster of two AML patients. Figure 18 (Example 5) is an analysis of differential expression of a core membrane protein molecule in differential genes of two AML patients. Figure 19 (Example 5) is an analysis of the genomics, CNVs, mutations, etc. of two AML patients. FIG. 20 (Example 6) is the phenotype detection of a single-cell suspension (mini-capsule tube) of tumor tissue (peripheral blood, bone marrow combined with peripheral blood) by flow cytometry on day 0 in three AML patients. Figure 21 (Example 6) shows the detection of total cell (including tumor cells and immune cells) viability in a capsule tube by the CTG method on day 14 in three AML patients. Figure 22 (Example 6) shows the phenotype of tumor tissue (tumor cells and immune cells) inside a mini capsule tube detected by FACS on day 14 in three patients. FIG. 23 (Example 7) is the phenotype detection of a single-cell suspension (mini-capsule tube) of tumor tissue (bone marrow combined with peripheral blood) by flow cytometry on day 0 in one AML patient. Fig. 24 (Example 7) shows the detection of the viability of all cells (including tumor cells and immune cells) in a capsule tube by the CTG method on day 14 in one AML patient. Figure 25 (Example 7) shows the ratio of tumor tissue (tumor cells and immune cells) in a mini capsule tube detected by FACS on day 14 in one patient. FIG. 26 (Example 8) is the phenotype detection of a single-cell suspension (mini-capsule tube) of tumor tissue (bone marrow) by flow cytometry on day 0 in two AML patients. FIG. 27 (Example 8) is a detection of the survival rate of total cells (including tumor cells and immune cells) in a capsule tube by the CTG method on day 10 in two AML patients, comprising two patients inoculated with the same mouse experiment (two patients and one mouse) and one typical patient inoculated with one mouse experiment (one patient and one mouse). Figure 28 (Example 8) shows the ratio of tumor tissue (tumor cells and immune cells) in a mini capsule tube detected by FACS on day 10 in two patients. Specific details for implementing the invention
[0051] The present invention is further explained below through the methods of the examples, but the present invention is not limited to the scope of the examples. Experimental methods for which specific conditions are not specified in the following examples are selected according to conventional methods and conditions or product descriptions.
[0052] Example 1: Rapid functional screening and potential biomarker identification for immunotherapy in an ovarian cancer patient
[0053] 1. Preparation of experimental animals and sample collection
[0054] In this experiment, 6-8 week old Balb / c Nude mice were purchased from a supplier (purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd.) and reared in an SPF-rated animal facility, and the animals were reared adaptively for at least 3 days prior to the start of the experiment.
[0055] Fresh tumor samples from the patient were collected, placed in anticoagulant tubes, transported via a cold chain (2–8°C), and transferred to a central laboratory in a short time.
[0056] 2. Cell Treatment
[0057] Non-tumor and necrotic tissues were removed from the patient tumor sample, and the tumor sample was cut into tissue fragments 1–2 mm in size. The fragments were rinsed with HBSS buffer containing 1% PSB (penicillin + amphotericin B) and centrifuged to collect the tumor tissue fragments. They were digested with 1× collagenase at 37°C for 1–2 h. The above classification method is as follows.
[0058] Digestion was completed in serum-containing medium (RPMI1640, purchased from Gibco), and the cell suspension was collected using a 70 μM filter; the supernatant was removed by centrifugation at 1000 rpm for 5 minutes, and the cell pellet was collected; lysis was performed for 5 minutes at 4°C using 3–5 times erythrocyte lysis solution (pH adjusted to 7.2 with 139.6 mmol / L NH4Cl, 16.96 mmol / L Tris, and 1 mol / L HCl), the supernatant was removed by centrifugation at 1000 rpm for 5 minutes, the cell pellet was collected, and erythrocyte lysis was repeated twice; the cell pellet was resuspended in PBS containing 1% FBS, the supernatant was removed by centrifugation at 1000 rpm for 5 minutes, the cell pellet was collected, and the cell concentration was set to 1×10⁶ 8 It was adjusted to cell / ml.
[0059] 20 μl / 10 7 Anti-CD45 MicroBeads human or Anti-CD45 MicroBeads human and Anti-Fibroblast MicroBeads human were added at cell concentrations and incubated at room temperature for 30 minutes; the magnetic beads were gently washed with PBS containing 1% FBS, centrifuged at 1000 rpm for 5 minutes to remove the supernatant, and the cell pellet was resuspended in PBS containing 1% FBS; the magnetic beads were mounted on a sorting device (LS column, Milternyi Biotec), the LS column was washed twice with PBS containing 1% FBS, and the liquid flowing down from the LS column (tumor cells) and the cells inside the LS column (concentrated immune cells) were collected, respectively; the collected cell suspension was centrifuged at 1000 rpm for 5 minutes to remove the supernatant, resuspended in cell culture medium (purchased from Gibco), and counted.
[0060] Generally, by purifying tumor tissue with two types of microbeads—Anti-CD45 Microbeads human and Anti-Fibroblast Microbeads human—immune cells and stromal fibroblasts within the tumor tissue microenvironment must be retained. However, if the infiltration of immune cells within some tumor tissues is too high, exceeding half the ratio as in solid tumor pleural ascites delivery samples, only CD45 antibody microbeads can be added to concentrate immune cells.
[0061] 3. Detection and Data Analysis by Flow Cytometry
[0062] Single-cell suspensions of patient tumor tissue samples before purification, tumor cells after purification, and concentrated immune cells (including CD3+T) were each taken, and different mixed suspensions of tumor cells and immune cells at specific ratios (1.5:1–15:1) were prepared in amounts of approximately 0.1 M–0.3 M (million cells) each. Each sample suspension was divided into several portions according to the experimental purpose, and the corresponding flow cytometry antibody mixture was added. A compensating experimental group for control, such as direct labeling, was established, and the samples were incubated in the dark at 2–8°C for 25–30 minutes. The preliminary FACS panel for ovarian cancer consists of antibodies such as 7AAD, CD45, CD3, CD8, CD270, PD1, CD68, or CD25.
[0063] After antibody labeling was completed, PBS containing 2% FBS was added, and the supernatant was removed by centrifugation at 600 g at 4°C for 5 minutes; the cell pellet was resuspended in 250 μl of PBS containing 2% FBS (purchased from Gibco) and mechanical detection was performed by flow cytometry. Data detected by flow cytometry were analyzed using Flowjo software.
[0064] 4. Cell loading tube
[0065] A capsule device, i.e., a PVDF tube with a diameter of 1 to 2 mm, was taken out of a biological safety cabinet, with an average pore diameter permeability size of approximately 500 kDa molecular weight, and before filling with cell suspension, the PVDF tube underwent treatments such as activation with anhydrous ethanol (or activation with methanol, etc.), rinsing with ultrapure water, and autoclaving. Among them, a capsule tube 1.5 cm in length was taken and repeatedly rinsed with cell culture medium (purchased from Gibco).
[0066] The samples were analyzed according to flow cytometry, and CD45-tumor cells and CD3+ lymphocytes were uniformly mixed in a constant ratio (1.5:1 to 15:1) such that CD8+ T cells accounted for at least 0.5% of the total live cells, then placed in a PVDF tube and sealed.
[0067] 5. Vaccination and Administration
[0068] The above PVDF tubes were randomly inoculated subcutaneously into mice using a puncture needle, the wounds were sealed with medical tissue adhesive (purchased from 3M), and the control group and the treatment group (e.g., 1. paclitaxel, cisplatin, and Avastin / Bevacizumab; 2. PD1 antibody; 3. combination of PD1 antibody and PARP inhibitor niraparib; 4. niraparib) were randomly assigned and administered to the mice in the treatment group.
[0069] 6. Cell Vitality and Phenotype Detection
[0070] After 3 to 21 days of administration (day 10), mice were euthanized, and PVDF tubes were removed to quantitatively measure cell viability using CellTiter-Glo chemiluminescence. The relative ratio and phenotype of tumor cells and immune cells within the PVDF tubes were detected using a flow cytometer, and changes in the molecular biological information of tumor cells and immune cells within the PVDF tubes were detected using molecular biological methods (RNA-seq, DNA-seq technology).
[0071] 7. Data Analysis
[0072] Screening by flow cytometry (FACS) day 0: identification of the relative ratio and phenotype of early tumor cells and immune cells. Flow cytometry data of mixed cells within the capsule showed that CD45-tumor cells: CD45+CD3+T immune cells = 1.6:1, CD8+% = 3.1%. Additionally, T lymphocytes within the tumor, particularly CD8-activated cells, highly expressed the PD1 molecule, while CD8+T cells also weakly expressed the two immune checkpoint molecules CD270 and PD1, as shown in Figure 2.
[0073] Day 10, the end time of the in vivo experiment: The proliferative vitality of all cells in the administration group was calculated based on the cell vitality value in the control group (e.g., shown in Fig. 3), and the results of the efficacy of the test drug were calculated.
[0074] Day 10, the end point of the in vivo experiment: The relative ratio of tumor cells to immune cells and phenotypic differences in PVDF tubes were detected using a flow cytometer (e.g., as shown in Figure 4). The detection results were analyzed using Flowjo software. CTG and FACS detections on Day 10 show that PD1 antibodies can effectively mobilize the patient's autoimmune cells to inhibit the proliferation and metabolism of ovarian cancer tumor cells, regardless of whether the PD1 antibody is administered in combination with a PARP inhibitor or in a PD1 monotherapy group. Furthermore, along with the blockade and downregulation of PD1 antibodies by PD1 molecules, CD270 molecules (HVEM) were upregulated to a certain degree, regardless of whether the PD1 antibody is administered in combination with a PARP inhibitor or in a PD1 monotherapy group.
[0075] Changes in molecular biological information of tumor cells and immune cells within PVDF capsule tubes of clinical samples on day 0 or day 10 were detected using molecular biological methods (omics technologies such as DNA-seq and RNA-seq).
[0076] Accordingly, the present invention provides an “IO” (Immuno-Oncology Fast In Vivo Efficacy test) technology for a rapid screening method of immunotherapies, and the method is also used in each of the following examples.
[0077] Example 2: Rapid functional screening and potential biomarker identification for immunotherapy in an ovarian cancer patient
[0078] 1. The preparation of experimental animals, sample collection, cell processing, detection and data analysis methods by flow cytometry, and cell sealing requirements are the same as in Example 1.
[0079] 2. Vaccination and Administration
[0080] The above PVDF tubes were randomly injected subcutaneously into mice using a puncture needle, the wounds were sealed with medical tissue adhesive (purchased from 3M), and the control group and treatment group (e.g., 1. combination therapy with paclitaxel, cisplatin, and Bevacizumab; 2. PD1 antibody; 3. combination therapy with PD1 antibody and Bevacizumab; 4. combination therapy with PD1 antibody and cisplatin) were randomly selected and administered to the mice in the treatment group.
[0081] 3. Cell Vitality and Phenotype Detection
[0082] After 3 to 21 days of administration (day 10), mice were euthanized, and PVDF tubes were removed to quantitatively measure cell viability using CellTiter-Glo chemiluminescence. The relative ratio of tumor cells to immune cells and the baseline phenotype within the PVDF tubes were detected using a flow cytometer.
[0083] 4. Data Analysis
[0084] Screening by flow cytometry (FACS) day 0: identification of the relative ratio and phenotype of early tumor cells and immune cells. Flow cytometry data of mixed cells within the capsule suggested that the ratio of CD45-tumor cells to CD45+CD3+T immune cells was approximately 2.91:1, and the CD8+ percentage in live cells was 0.81%. Infiltrating T lymphocytes within the tumor weakly expressed PD1 molecules but significantly overexpressed CD270 (e.g., illustrated in Fig. 5).
[0085] Based on the cell vitality values in the control group (e.g., as shown in Fig. 6) during the in vivo experiment node day 10, the proliferative vitality of all cells in the administration group was calculated, and furthermore, the results of the efficacy of the test drug were calculated.
[0086] In vivo experiment node day 10: The relative ratio of tumor cells and immune cells and phenotypic differences in PVDF tubes were detected using a flow cytometer (e.g., as shown in Fig. 7). The detection results were analyzed and statistically analyzed using Flowjo software.
[0087] Based on the experimental results in Figures 6 and 7, in addition to the paclitaxel, cisplatin, and Bevacizumab combination drug group, live CD45-tumor cells in the capsule tubes accounted for at least half on day 10; the PD1 monotherapy group, the targeted drug Bevacizumab combination group, or the cisplatin combination group could all significantly inhibit the overall survival rate of tumor tissue (including tumor cells and immune cells) compared to the control group, and as the tumor progressed, CD270+PD1+double-positive TILs were concentrated within the mini-capsule, showing a down-regulatory trend in the PD1 monotherapy group. Combined with the flow cytometry data typing from Example 1, this demonstrates that effective expression of the CD270 molecule in solid tumors is a potential positive biomarker for the treatment of the immune checkpoint inhibitor PD1 antibody, and that the response to immunotherapy remained good even in patients with initially weak PD1 expression but significant CD270 expression.
[0088] Changes in molecular biological information of tumor cells and immune cells within PVDF capsule tubes in clinical samples were detected on day 0 or day 10 using molecular biological methods (omics technologies such as DNA-seq and RNA-seq).
[0089] Example 3: Rapid functional screening for immunotherapy in one ovarian cancer patient
[0090] 1. The experimental animals, sample collection, and cell treatment are the same as in Example 1.
[0091] 2. Detection and Data Analysis by Flow Cytometry
[0092] QC Identification: Single-cell suspensions of patient tumor tissue samples before purification, tumor cells after purification, and concentrated immune cells (including CD3+T) eluted from the column were each taken. Suspensions were prepared by mixing the tumor cells after purification and the immune cells in a specific ratio (1.5:1 to 15:1) (note that if the viability of immune cells eluted from the column is less than 20%, subsequent experiments and manipulations cannot be performed, and activated immune cells, in particular, are more likely to experience activation-induced apoptosis). Each sample suspension was divided into several portions according to the experimental purpose, the corresponding flow cytometry antibody mixture was added, and a compensatory experimental group for control, such as direct labeling, was established. The samples were incubated in the dark at 2–8°C for 25–30 minutes. The preliminary FACS panel for ovarian cancer consists of antibodies such as 7AAD, CD45, CD3, CD8, CD270, PD1, CD68, or CD25.
[0093] After antibody labeling was completed, PBS containing 2% FBS was added, and the supernatant was removed by centrifugation at 600 g at 4°C for 5 minutes; the cell pellet was resuspended in 250 μl of PBS containing 2% FBS (purchased from Gibco) and mechanical detection was performed by flow cytometry. Data detected by flow cytometry were analyzed using Flowjo software.
[0094] 3. Cell loading tube
[0095] The basic operation steps are the same as in Example 1.
[0096] Based on the data analyzed in the flow cytometry step, CD45-tumor cells and CD3+T cells were uniformly mixed in a certain ratio (1.5:1 to 15:1) such that CD8+T cells accounted for at least 0.5% of the total live cells, then placed in a PVDF tube and sealed. In the corresponding example, the tumor sample before purification was also sealed and tested.
[0097] 4. Vaccination and Administration
[0098] The above PVDF tubes were randomly inoculated subcutaneously into mice using a puncture needle, the wounds were sealed with medical tissue adhesive (purchased from 3M), and the control group and treatment group (e.g., 1. combination therapy with paclitaxel, cisplatin, and Bevacizumab; 2. PD1 antibody; 3. combination therapy with PD1 antibody and PARP inhibitor Niraparib; 4. PARP inhibitor Niraparib) were randomly assigned and administered to the mice in the treatment group.
[0099] 5. Cell Vitality and Phenotype Detection
[0100] After 3 to 21 days of administration (day 10), mice were euthanized, and PVDF tubes were removed to quantitatively measure cell viability using CellTiter-Glo chemiluminescence. The relative ratio of tumor cells to immune cells and the baseline phenotype within the PVDF tubes were detected using a flow cytometer.
[0101] 6. Data Analysis
[0102] Screening by flow cytometry (FACS) day 0: identification of the relative ratio and phenotype of early tumor cells and immune cells, (1) in the tumor tissue before purification, the ratio of tumor cells CD45- and CD3+ T cells (C / T) = 0.3 and CD8+T% = 11.5, meaning the tumor sample from the patient was rich in TILs; (2) after purification, the tumor tissue cells contained only 2.84% immune cells, with a C / T value of 49.1 and CD8+% = 0.448%; (3) after purification, the total vitality of the immune cell population was approximately 43%, maintaining the phenotype of the basal cells before purification; and (4) after the addition of immune cells to the tumor tissue sample, the C / T value was 8 and CD8+% = 2.45%. Infiltrative T lymphocytes within the tumor weakly express CD270 molecules and highly express PD1 molecules, suggesting that they may show a good response to PD1 antibodies (e.g., illustrated in Fig. 8).
[0103] At the end of the in vivo experiment on day 10, the proliferative vitality of all cells in the administration group was calculated based on the cell vitality value in the control group (e.g., shown in Fig. 9), and furthermore, the results of the efficacy of the test drug were calculated.
[0104] Day 10, the end point of the in vivo experiment: The relative ratio of tumor cells and immune cells and phenotypic differences in the PVDF tubes were detected using a flow cytometer (e.g., as shown in Figure 10). The detection results were analyzed and statistically analyzed using Flowjo software.
[0105] Based on the experimental results in Figs. 9 and 10, in the day10 mini-capsule, CD45- tumor cells predominated regardless of whether the tumor tissue sample was unpurified or the sample with autologous TILs added to it, and CD45- cells were approximately 2 to 3 times more numerous than CD45+ cells (Fig. 10); while the CTG data for the unpurified tumor tissue sample showed that neither treatment, including the clinical first-line drug, could significantly reduce the total cell viability of the corresponding tissue sample; however, after adding autologous TILs to the tumor sample, the clinical first-line drug combination could weakly reduce the total cell viability of the corresponding sample, and although neither the PD1 antibody nor the PARP inhibitor of a single drug could suppress the overall viability of the tumor tissue, the combined administration of the PD1 antibody and the PARP inhibitor could significantly suppress the overall proliferation and activity of the tumor tissue (Fig. 9). Interestingly, the combined administration of a PD1 antibody and a PARP inhibitor significantly increased the proportion of the CD270+PD1-T cell subpopulation and relatively decreased the proportion of PD1+CD270- and PD1-CD270-T cells (Fig. 10), which again suggests that the CD270 molecule may be a potential indicator biomarker for PD1 antibody therapy.
[0106] Example 4: Rapid functional screening for immunotherapy of a lung cancer patient
[0107] 1. The experimental animals, sample collection, and cell treatment are the same as in Example 1.
[0108] 2. Detection and Data Analysis by Flow Cytometry
[0109] Single-cell suspensions of patient tumor tissue samples before purification, as well as tumor cells and concentrated immune cells after purification, were taken separately. Then, different mixed suspensions of tumor cells and CD3+T cells were prepared at specific ratios (1.5:1–15:1), with concentrations ranging from approximately 0.1 M to 0.3 M. Each sample suspension was divided into several portions according to the experimental purpose, and corresponding control compensation groups—such as flow cytometry antibody mixtures and direct labeling—were established and incubated in the dark at 2–8°C for 25–30 min. The preliminary FACS panel for the relevant lung cancer patients included 7AAD, CD45, CD3, and CD8. After antibody labeling was completed, PBS containing 2% FBS was added, and the mixture was centrifuged at 4°C at 600 g for 5 min to remove the supernatant; the cell pellet was resuspended in 250 μl of PBS containing 2% FBS (purchased from Gibco) to perform mechanical detection by flow cytometry. Data analysis detected by flow cytometry was performed using Flowjo software.
[0110] 3. Cell loading tube
[0111] Capsule devices, i.e., PVDF tubes with a diameter of 1 to 2 mm, were taken out of a biological safety cabinet, with an average pore diameter permeability size of approximately 500 kDa molecular weight, and the PVDF tubes underwent treatments such as anhydrous ethanol activation, ultrapure water rinsing, and autoclaving before being filled with cell suspension. Among them, a 1.5 cm long capsule tube was taken and repeatedly rinsed with cell culture medium (purchased from Gibco).
[0112] Based on the results of flow cytometry analysis, tumor cells and CD3+ lymphocytes were uniformly mixed in a constant ratio (1.5:1 to 15:1) (with CD8+ T cells accounting for at least 0.5% of the total live cells) and then placed in a PVDF tube and sealed.
[0113] 4. Vaccination and Administration
[0114] The above PVDF tubes were randomly injected subcutaneously into mice using a puncture needle, the wounds were sealed with medical tissue adhesive (purchased from 3M), and the control group and the treatment group (e.g., 1. PD1 antibody; 2. combination of PD1 antibody and HDAC inhibitor Chidamide) were randomly selected and administered to the mice in the treatment group.
[0115] 5. Cell Vitality and Phenotype Detection
[0116] After 3 to 21 days of administration (day 14), mice were euthanized, and PVDF tubes were removed. Cell vitality was quantitatively measured by CellTiter-Glo chemiluminescence, and the relative ratio of tumor cells to immune cells and the basic phenotype within the PVDF tubes were detected using a flow cytometer.
[0117] 6. Data Analysis
[0118] Screening by flow cytometry (FACS) day 0: identification of the relative ratio and phenotype of early tumor cells and immune cells, flow cytometry data of mixed cells within the capsule suggest that CD45-tumor cells:CD45+CD3+T immune cells are approximately 15:1 and CD8+%=2.2% (e.g., shown in Fig. 11).
[0119] At the end of the in vivo experiment on day 14, the proliferative vitality of all cells in the administration group was calculated based on the cell vitality value in the control group (e.g., shown in Fig. 12), and furthermore, the results of the efficacy of the test drug were calculated.
[0120] End of in vivo experiment: The relative ratio of tumor cells and immune cells and phenotypic differences in the PVDF tubes were detected using a flow cytometer (e.g., as shown in Fig. 13). The detection results were analyzed using Flowjo software.
[0121] Based on the experimental results in Figures 12 and 13, on day 14, the live cells in the capsule tube were still predominantly CD45-tumor cells, accounting for about 60–75%; after treatment with PD1 antibody, although it can promote the survival of CD8+ T cells, it cannot downregulate the overall cellular vitality of tumor cells and immune cells; and after the combination of PD1 antibody and the HDAC inhibitor Chidamide, it can significantly reduce overall cellular activity (ATP activity). Therefore, PD1 antibody monotherapy is not suitable for the lung cancer patient in question, and combination therapy with immunotherapy and chemo-targeted drugs is recommended.
[0122] Example 5: Rapid functional screening and potential biomarker identification for immunotherapy in two acute myeloid leukemia (AML) patients
[0123] 1. Experimental Animals and Sample Collection
[0124] In this experiment, 6-8 week old Balb / c Nude mice were purchased from a supplier (purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd.) and reared in an SPF-rated animal facility, and the animals were reared adaptively for at least 3 days prior to the start of the experiment.
[0125] Fresh peripheral blood samples (in the acute phase of AML patients) from two AML patients were collected, placed in anticoagulant tubes, transported via a cold chain (2–8°C), and transferred to a central laboratory in a short time.
[0126] 2. Cell Treatment
[0127] Peripheral blood samples from different patients were transferred to a biological safety cabinet, and a gradient centrifuge gel (purchased from SIGMA) with a density of 1.077 g / mL was restored to room temperature and added to two new centrifuge tubes; two peripheral blood samples from the patient were each added to one centrifuge tube, the liquid was slowly placed into the centrifuge, the temperature was set to 20–25°C (room temperature), and the lifting and lowering speeds were both 1 or 0, 400 g, and 20 min; upon completion of centrifugation, the centrifuge tube was slowly moved to remove the turbid cell layer of the middle layer (containing a large amount of mononuclear cells), washed with 15 ml PBS (purchased from Gibco), centrifuged at 1500 rpm for 5 min to remove the supernatant, and the normal cell suspension was centrifuged; If necessary, 3 to 5 times the amount of red blood cell lysis solution (purchased from Invitrogen) was added and lysed for 5 minutes, and the supernatant was removed by centrifugation at 1500 rpm for 5 minutes; the cells were resuspended in cell culture medium (purchased from Gibco) and counted.
[0128] 3. Detection and Data Analysis by Flow Cytometry
[0129] 0.3 M peripheral blood cells were taken, and different flow cytometry antibodies were selected according to the experimental purpose. Staining and compensation settings were performed, and the cells were incubated in the dark at 2–8°C for 25–30 minutes. Antibody labeling was then performed, with the flow cytometry panels commonly used for AML patients being 7AAD, CD45, CD3, CD8, CD33, CD38, CD20, CD25, or PD1. After antibody labeling was completed, PBS containing 2% FBS (purchased from Gibco) was added, and the mixture was centrifuged at 600 g at 4°C for 5 minutes to remove the supernatant; the cell pellet was resuspended by adding 250 μl of PBS containing 2% FBS (purchased from Gibco) and detected using a flow cytometer. Analysis of data detected by flow cytometry: Data detected by flow cytometry was analyzed using Flowjo software.
[0130] 4. Cell loading tube
[0131] A capsule device, i.e., a PVDF tube with a diameter of 1 to 2 mm, was taken out of a biological safety cabinet (since the average pore diameter of the material is approximately 300 kDa-700 kDa, the entry of high-molecular-weight proteins, etc., is permitted, but the free entry of cells is not permitted), and before filling with cell suspension, the PVDF tube was subjected to treatments such as anhydrous ethanol activation, ultrapure water rinsing, and autoclaving. A 1.5 cm long capsule tube was taken and repeatedly rinsed with cell culture medium (purchased from Gibco).
[0132] Analysis was performed according to the flow cytometry of step (4), and quality control analysis was performed, and tumor cells (or non-CD45) such that the proportion of CD8+T cells was greater than at least 0.5% (default value for immunodrug action). high SSC-A low cell) and CD45 high SSC-A lowCD3+T lymphocytes were uniformly mixed at a constant ratio (1.5:1 to 15:1), placed in a PVDF tube, and sealed.
[0133] 5. Vaccination and Administration
[0134] The above PVDF tubes were randomly injected subcutaneously into mice using a puncture needle, and the wounds were sealed with medical tissue adhesive (purchased from 3M). The mice in the treatment groups were then randomly assigned to a control group and different treatment groups (e.g., PD1 antibody, CD38 antibody Dara, targeted drug Bcl2 inhibitor Venetoclax, HDAC inhibitor Chidamide, etc., either as a single drug or a combination).
[0135] 6. Cell Vitality and Phenotype Detection
[0136] After 3 to 21 days of administration (e.g., day 14), mice were euthanized, and PVDF tubes were removed and total cell viability was quantitatively measured by CellTiter-Glo chemiluminescence; changes in the relative ratio of tumor cells and immune cells and phenotype within the PVDF tubes were detected using a flow cytometer; and changes in molecular biological information of tumor cells and immune cells within the PVDF capsule tubes on day 0 or day 10 in clinical samples were detected using molecular biological methods (RNA-seq, DNA-seq technology, etc.).
[0137] 7. Data Analysis
[0138] Classification by flow cytometry day 0: Relative ratios of early tumor cells and immune cells and phenotypic identification in two AML patients (123#, 124#) (e.g., illustrated in Fig. 14). CD8+ T cells in patient 123# accounted for 0.21% of total live cells (it is presumed that this patient may not be sensitive to PD1 antibodies), C / T (CD45 lowThe ratio of CD33+CD38+ tumor cells to CD3+T is about 15:1 (still having more CD38-tumor cells), whereas in patient 124#, the CD8+T% is about 3.48% and the C / T ratio is about 6:1.
[0139] Day 14 CTG experiment calculated the proliferative vitality of all cells in the administration group based on the cell vitality value in the control group (e.g., shown in Fig. 15), and further calculated the results of the efficacy of the test drug.
[0140] On Day 14, the relative ratio of tumor cells to immune cells in PVDF tubes was detected by flow cytometry; and the difference in tumor cells to immune cells between the drug group and the control group (e.g., shown in Fig. 16) was compared. The detection results were analyzed using Flowjo software.
[0141] According to the analysis of the Day 14 CTG and FACS data above, for patients #123 and #124 on Day 14, the live cells inside the capsule tube were still CD45- / low Tumor cells (e.g., AML cancer blasts) account for the majority, and about 5% to 10% of CD45 high SSC-A lowLymphocytes were present (Figure 16a uses 124# as an example). Patient 124# (Immune Responder) showed a good response to the checkpoint inhibitor PD1 antibody (the CTG inhibitory effect in Figure 12 was more than half), which was consistent with high levels of CD8+ T cells on day 0, significantly reducing the proportion of AML blasts in live cells and relatively improving the proportion of CD3+CD8+ (Figure 16b), whereas this phenomenon was not observed in patient 123# (Immune Non-responder). In addition, the CD38 antibody, which possesses antibody-dependent cytotoxicity (ADCC) and antibody-antibody-dependent macrophage phagocytosis (ADCP), also exhibited a certain reactivity in the system; although the effect was relatively weaker compared to the PD1 antibody, this was closely related to the high expression of the CD38 antigen in the cancer cells of patient #124, whereas in patient #123 who did not respond to the CD38-Ab monotherapy, CD38 was weakly expressed at approximately 10.7% (Fig. 14). Therefore, the activity and function of NK cells and monocyte macrophages are retained even during the collection of immune cells on day 0 in the system, and both are CD45+.
[0142] 8. Biological Information Analysis
[0143] Bioinformatics fingerprints of the patient's tumor cells and immune cells within the PVDF capsule tube were detected on day 0 using molecular biological methods (RNA-seq and DNA-seq) to identify the patient's biomarkers regarding immunodrug responsiveness, thereby suggesting molecular pathophysiological evidence for the onset and progression of the disease.
[0144] RNA-seq analysis of transcriptome differences between two patients:
[0145] (1) Differential gene signaling pathway analysis: As shown in Figures 17a and 17b, 123# immune-non-responsive patients had high tumor proliferation activity (e.g., CCDN1, PLK1, MCM2), strong tumor microenvironment remodeling ability, high expression of neovascularization-related markers (e.g., VEGFC, ANGPT2, FLT1, VWF), and low function of T cells, particularly effector T cells. 124# immune-responsive patients had low tumor proliferation and angiogenesis ability, while T cells (e.g., IFNγ) and neutrophils (ELANE, MPO, PRTN3) had relatively strong function, such as equivalent effector function.
[0146] (2) Discovery of potential key biomarkers for immunotherapy in AML patients (subgroup of membrane proteins): As shown in Fig. 18, differential expression analysis of membrane proteins revealed that, compared to immune-responsive patients, immune-non-responsive patients expressed significantly higher levels of membrane proteins favorable for tumor development and progression, such as oncogenes or tumor susceptibility genes (ITGA4, ITGA2B, ITGB3, PDLIM1, ADA, CAVIN1, CAVIN2, C3orf14, TEC, EPCAM, CD109, etc.) and immunosuppression-related genes (CSF1, CD274 / PDL1), as well as novel, previously unreported tumor target molecules including SLC9A3R2 (SLC9A3 regulator 2), PIGW (phosphatidylinositol glycan anchor biosynthesis class W), CDH26 (cadherin 26), and PPP1R16B (protein phosphatase 1 regulatory subunit 16B). Membrane molecules are not only biomarkers for hematological tumors but may also be major potential biomarkers for the development and progression of a wide range of tumors.
[0147] DNA-seq analysis of genomic differences between two AML patients:
[0148] As shown in Figure 19, the WES-CNV signal is highly variable and does not suggest obvious deletion or amplification; known biomarkers associated with AML, including fusion genes (ABL1~BCR, CRLF2, JAK2-BRAF, NOTCH1) and mutant genes (FBXW7, JAK1, KRAS, NOTCH1, NPM1, FLT3, KIT, CEBPA), have not yet been found to be positive. In other words, in terms of the genome, key mutations of the genes reported in the two patients were not found.
[0149] Example 6: Rapid functional screening and potential biomarker identification for immunotherapy in three patients with acute myeloid leukemia (AML)
[0150] 1. The preparation of experimental animals is the same as in Example 5.
[0151] 2. Sample collection
[0152] Fresh peripheral blood and / or bone marrow samples (in the acute phase of AML patients) from three AML patients were collected, placed in anticoagulant tubes, transported via a cold chain (2–8°C), and transferred to a central laboratory in a short time.
[0153] 3. Cell treatment and detection by flow cytometry are the same as in Example 5.
[0154] 4. Cell loading tube
[0155] It is similar to Example 4. Here, bone marrow and blood samples from some patients were mixed in a ratio of 4:1 to 5:1 to include circulating peripheral blood cells in the tumor tissue samples, thereby simulating human microenvironment functions to the maximum extent. Quality control analysis was performed based on flow cytometry data, and tumor cells (or non-CD45) were selected so that the proportion of CD8+ T cells was greater than at least 0.5% (default value for immunodrug action).high SSC-A low cell) and CD45 high SSC-A low CD3+T lymphocytes were uniformly mixed at a constant ratio (C / T = 1.5:1–15:1), placed in a PVDF tube, and sealed.
[0156] 5. Vaccination and Administration
[0157] The same as in Example 4, a control group and different administration groups (e.g., CD38 antibody, combination of CD38 antibody and PD1 antibody, combination of PD1 antibody and decitabine, PD1 antibody) were randomly selected and administered to mice in the administration group.
[0158] 6. Data Analysis
[0159] Classification by flow cytometry (FACS) day 0: As shown in Fig. 20, patient 128's blood C / T (CD38+Cancer / CD3+T) = 4 and the mixed bone marrow and blood sample C / T = 7.5; patient 129's blood C / T = 1.1 (since more cancer blasts do not express CD38, i.e., the actual C / T value of the patient is greater than 1.5) and the mixed bone marrow and blood sample C / T = 5.3; and patient 131's bone marrow sample C / T = 4.5. The bone marrow tumor cells of all three of these patients highly expressed the CD38 molecule (about 70% to 80%), and the CD8+T% was 1% to 10%.
[0160] Day 14 CTG experiment calculated the proliferative vitality of all cells in the administration group based on the cell vitality value in the control group (e.g., shown in Fig. 21), and further calculated the results of the efficacy of the test drug.
[0161] On Day 14, the relative ratio of tumor cells to immune cells in PVDF tubes was detected by flow cytometry; and the difference in tumor cells to immune cells between the drug group and the control group (e.g., shown in Fig. 22) was compared. The detection results were analyzed using Flowjo software.
[0162] The results of Figures 20, 21, and 22 indicate that although all three patients expressed high levels of the CD38 target protein, patients 128 and 129 showed little significant response to the CD38 antibody (Figure 21 suggests that the total number of live cells did not decrease after drug treatment; Figure 22 suggests that cancer blasts still accounted for a dominant proportion in the mini-capsule), whereas patient 131 showed a good response (Figure 19). Additionally, although TIL cells were abundant in the bone marrow and / or blood of all three patients (approximately 5% to 17%), only patient 131 showed a good response to the PD1 antibody, specifically the combination of the PD1 antibody and decitabine (5aza).
[0163] Bioinformatics fingerprints of the patient's tumor cells and immune cells within the PVDF capsule tube were detected using molecular biological methods (RNA-seq and DNA-seq) on day 0 or day 14 to discover and evaluate the patient's biomarkers regarding immunodrug sensitivity and tolerance.
[0164] Example 7: Rapid functional screening for immunotherapy in one acute myeloid leukemia (AML) patient
[0165] 1. The experimental animals are the same as in Example 5.
[0166] 2. Sample collection
[0167] Fresh peripheral blood and bone marrow samples (in the acute phase of AML patients) were collected from one AML patient, placed in anticoagulant tubes, transported via a cold chain (2–8°C), and transferred to a central laboratory in a short time.
[0168] 3. Cell processing, detection by flow cytometry, and data analysis are the same as in Example 5.
[0169] 4. Cell loading tube
[0170] Similar to Example 6, the patient's bone marrow and blood samples were mixed in a ratio of 4:1 to 5:1 to include circulating peripheral blood cells in the tumor tissue sample, thereby simulating human microenvironment functions to the maximum extent. Quality control analysis was performed based on flow cytometry data, revealing CD8+T%=0.466% (approaching the threshold of 0.5%), tumor cells (CD38+CD33+tumor cells), and CD45 high SSC-A low A CD3+T ratio of 8 (falling within the range of C / T = 1.5:1 to 15:1) was detected, follow-up exploratory experiments were performed, and the sample was placed in a PVDF tube and sealed.
[0171] 5. Vaccination and Administration
[0172] Same as Example 4, a control group and different administration groups (e.g., bcl2 inhibitor Venetoclax, CD38 antibody, CD38 antibody combined with Chidamide, CD38 antibody combined with 5AZA, CD38 antibody combined with Venetoclax, PD1 antibody, PD1 antibody combined with 5AZA, etc.) were randomly selected and administered to mice in the administration group.
[0173] 6. Cell vitality and phenotype detection are the same as in Example 5.
[0174] 7. Data Analysis
[0175] Classification by flow cytometry (FACS) day 0: As shown in Fig. 23, the bone marrow and blood mixed sample of patient #160 had a C / T=8 (meaning more tumor cells do not express CD38, i.e., the patient's actual C / T value is much greater than 8) and CD8+T%=0.466%.
[0176] Day 14 CTG experiment calculated the proliferative vitality of all cells in the administration group based on the cell vitality value in the control group (e.g., shown in Fig. 24), and further calculated the results of the efficacy of the test drug.
[0177] On Day 14, the relative ratio of tumor cells to immune cells in PVDF tubes was detected by flow cytometry; and the difference in tumor cells to immune cells between the drug group and the control group (e.g., shown in Fig. 25) was compared. The detection results were analyzed using Flowjo software.
[0178] The flow cytometry and CTG results for day 14 showed that the minicapsule contained CD45 low Tumor precursors / progenitor cells predominate, and lymphocytes account for about 20%, suggesting that none of the tested drugs significantly inhibited the cellular activity of the tumor tissue population. The experiment suggests that a high C / T ratio (>>8) and low CD8+% (<0.5%) may be the cause of non-response to immunotherapy in the patient.
[0179] Example 8: Rapid functional screening for immunotherapy of multiple (two) acute myeloid leukemia (AML) patients in the same mouse
[0180] 1. The experimental animals are the same as in Example 4.
[0181] 2. Sample collection
[0182] Fresh bone marrow samples were collected from two AML patients, placed in anticoagulant tubes, transported via a cold chain (2–8°C), and transferred to a central laboratory in a short time.
[0183] 3. Cell processing, detection and data analysis by flow cytometry, and cell loading tubes are the same as in Example 4.
[0184] 4. Vaccination and Administration
[0185] Capsules inoculated with bone marrow cells from two patients were prepared and subcutaneously injected into both sides of the mice. Each patient received three mini-capsule tubes (two patients and one mouse). The mice were randomly grouped, and control and treatment groups (e.g., CD38 antibody, PD1 antibody) were established and administered to the mice in the treatment group. Additionally, independent control and treatment experiments were conducted using conventional methods (one patient and one mouse), and some mini-capsule tubes were stored for FACS detection on day 10.
[0186] 5. Cell vitality and phenotype detection are the same as in Example 4.
[0187] 6. Data Analysis
[0188] Classification by flow cytometry day 0: As shown in Fig. 26, patient 228's bone marrow C / T (CD38+Cancer / CD3+T) = 12 and CD8+% = 0.57 (high C / T value and low CD8+% ratio suggest that the patient may not respond to T-cell immunotherapy); patient 232's bone marrow C / T = 8.5 and CD8+% = 0.85%. Both patients had low CD3+T ratios, and furthermore, the expression of PD1 and CD270 markers was very weak, suggesting that PD1 antibody treatment may not be effective.
[0189] On day 10, the CTG experiment calculated the proliferative vitality of all cells in the administration group based on the cell vitality value in the control group (e.g., shown in Fig. 27), and further calculated the results of the efficacy of the test drug.
[0190] On day 10, the relative ratio of tumor cells to immune cells in PVDF tubes was detected by flow cytometry; and the difference in tumor cells to immune cells between the drug group and the control group (e.g., shown in Fig. 28) was compared. The detection results were analyzed using Flowjo software.
[0191] Day 10 CTG and FACS results suggest that CD45-tumor cells still predominantly occupy the majority of the capsules in both patients (e.g., Fig. 28). Patient 228# AML was sensitive to CD38 antibody treatment, with total cell activity suppressed by approximately half (Fig. 27) and the ratio of CD45-tumor cells to CD45+ immune cells being lower compared to the control group (Fig. 28), whereas Patient 232# did not show significant responsiveness to CD38 antibodies despite high expression of CD38 antigens (Figs. 26 and 27; these differences in response may be due to differences in the density of CD38 tumor antigens among the patients and functional differences in ADCC, ADCP, etc., of myeloid and myeloid immune cells such as NKs, monocyte macrophages, and neutrophils); neither patient responded to PD1 antibodies, which is consistent with our initial prediction that this is due to the extremely low number of PD1+CD3+T cells in the patients' tumor microenvironments (Figs. 26 and 27). In addition, the detection of drug sensitivity in the same mouse model for both patients was consistent with the existing model data of one patient inoculated into one mouse (Fig. 27). Therefore, for rapid screening of in vivo immunodrug efficacy, multiple patient capsules can be loaded into the same mouse to perform the test in order to save costs and resources, and can be distinguished and tracked based on different inoculation sites (this experiment), different capsule sizes, and even colors.
[0192] The significant implications of the in vivo screening method for the functionality of the relevant immunodrug are summarized as follows.
[0193] (1) The data from Examples 1, 2, and 3 suggest that the method can effectively detect that some ovarian cancer patients with TIL-rich tumors and weak initial PD1 / PD1 expression may have a good response to PD1 antibodies. Significant expression or differential changes in CD270 in tumor-infiltrating lymphocytes may also be a potential biomarker for PD1 antibody therapy (no studies have been reported at present). Even if PD1 is abundantly expressed in tumor tissue, an imbalance in the ratio and abundance of tumor cells and immune cells can affect the response to immunotherapy, and the combination of immunotherapy and targeted therapy may be an effective pathway to overcome non-response to monotherapy (Example 4 also supports this claim).
[0194] (2) The data from Examples 5, 6, and 7 suggest that the method can effectively screen and distinguish differential responses in CD38+ / high and / or TIL-enriched blood cancer patients (e.g., AML) to in vivo immune responses to CD38 antibodies or PD1 antibodies. In addition to the discovery of known important cancer-promoting / tumor-susceptibility genes (these reported cancer-promoting genes accounted for more than 90% of all differential genes in the membrane molecules we analyzed, indirectly proving the reliability of the model), new potential therapeutic targets such as SLC9A3R2 (SLC9A3 regulator 2), PIGW (phosphatidylinositol glycan anchor biosynthesis class W), CDH26 (cadherin 26), and PPP1R16B (protein phosphatase 1 regulatory subunit 16B) were also identified. Thus, omics analysis mediated by rapid functional experiments is advantageous for the discovery and study of new targets.
[0195] (3) Example 8 shows the results of rapid in vivo screening of an immunodrug by loading tumor capsules from multiple patients with the same disease into the same mouse. This is consistent with the results of drug sensitivity testing from one patient in a conventional immunodeficient mouse, suggesting that it is advantageous for cost reduction and improved efficacy.
Claims
Claim 1 A polyvinylidene fluoride (PVDF) capsule tube containing cells, wherein the cells comprise tumor cells and immune cells suspended as single cells; The above tumor cells and immune cells are derived from fresh tumor tissue or body fluid of a clinical patient; the tumor tissue comprises tumor tissue resected by clinical surgery or biopsy of tumor tissue; the immune cells are autoimmune cells concentrated through the sorting of a single-cell suspension, and the tumor cells are tumor cells that flow through during the sorting of a single-cell suspension; the patient's autoimmune cells are derived from tumor-infiltrating lymphocytes within the patient's solid tumor tissue, or are lymphocytes concentrated from peripheral blood mononuclear cells derived from the patient's peripheral blood or bone marrow; the ratio of tumor cells to immune cells is 1.5:1 to 15:1; the proportion of CD8+ T cells in the total live cells is 0.5% to 15%; the average protein permeability of the capsule tube is 300 to 1,000 kda; and the body fluid comprises one or more of blood, bone marrow, pleural and ascites fluid and cerebrospinal fluid. Claim 2 In claim 1, the capsule tube having an average protein permeability of 500 to 700 kda. Claim 3 A capsule tube according to claim 1, wherein the capsule tube is pretreated by activation, ultrapure water rinsing, and high-pressure sterilization before use, and the activation is performed by rinsing the tube in anhydrous ethanol (dehydrated alcohol). Claim 4 In claim 1, the sorting device used for sorting comprises: (1) sorting magnetic beads, Anti-human CD45 MicroBeads, or Anti-human CD45 MicroBeads and Anti-human Fibroblast MicroBeads; and (2) a sorting device which is an LS column, comprising a capsule tube. Claim 5 In claim 4, a capsule tube in which the ratio of tumor cells to immune cells is in the range of 1.5:1 to 9:
1. Claim 6 A capsule tube according to claim 1, wherein the viability of the immune cells is greater than 20%. Claim 7 An animal model comprising a capsule tube of claim 1, wherein the tube is implanted subcutaneously or orthositely; said animal is a mouse; said mouse is an immunodeficient mouse selected from the group consisting of Balb / c Nude mouse, NCG mouse, NSG mouse, or NOD-scid mouse. Claim 8 An animal model according to claim 7, wherein the number of capsule tubes is 1 to 8. Claim 9 A method for rapidly screening the efficacy of an immunomodulatory drug, wherein the method comprises: (1) administering a drug to an animal model of claim 7; wherein the drug is an immunomodulatory drug in a solid, semi-solid, or liquid form; and wherein the drug is administered by intravenous injection, oral gastric tube nutrition, intraperitoneal injection, or subcutaneous injection; (2) detecting the total cell activity or immune cell activity of tumor cells and immune cells within a capsule tube, the relative ratio of tumor cells and immune cells, and the cell phenotype; wherein the method for detecting the total cell activity or immune cell activity is CTG; and the method for detecting the relative ratio and cell phenotype is flow cytometry (FACS). and (3) detect molecular biological information of tumor cells and immune cells within a capsule tube, wherein the method of detecting the biological information is DNA-seq or RNA-seq, and wherein steps (2) and (3) may be performed in any order; wherein in step (2), the FACS performs antibody labeling, wherein the antibody includes one or more of 7AAD, CD45, CD3, CD8, CD270, CD33, CD38, CD20, PDL1, PD1, CD68 and CD25; detect by flow cytometry, wherein after the antibody labeling is completed, PBS containing 2% FBS is added and then loaded for detection in the FACS; and analyze data with software, wherein the software is Flowjo, and one or more of the above steps. Claim 10 A method using a capsule tube according to claim 1 for manufacturing an animal model for rapidly screening the efficacy of an immunomodulatory drug, wherein the animal is an immunodeficient mouse; and the animal model is capable of simultaneously performing drug screening on 1 to 8 patients or 1 to 4 patients.
Citation Information
Patent Citations
Method of evaluating chemotherapeutic agents in vivo
WO1994025074A1
New pyridine carboxamides
WO2019154663A1
Method and device for drug screening
US20190154663A1
